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Abstract: Epigenetics plays a pivotal role in regulating gene expression in development, in response
to cellular stress or in disease states, in virtually all cell types. MicroRNAs (miRNAs) are short,
non-coding RNA molecules that mediate RNA silencing and regulate gene expression. miRNAs were
discovered in 1993 and have been extensively studied ever since. They can be expressed in
a tissue-specific manner and play a crucial role in tissue development and many biological processes.
miRNAs are responsible for changes in the cell epigenome because of their ability to modulate
gene expression post-transcriptionally. Recently, numerous studies have shown that miRNAs
and other epigenetic factors can regulate each other or cooperate in regulating several biological
processes. On the one hand, the expression of some miRNAs is silenced by DNA methylation,
and histone modifications have been demonstrated to modulate miRNA expression in many cell
types or disease states. On the other hand, miRNAs can directly target epigenetic factors, such as DNA
methyltransferases or histone deacetylases, thus regulating chromatin structure. Moreover, several
studies have reported coordinated actions between miRNAs and other epigenetic mechanisms
to reinforce the regulation of gene expression. This paper reviews multiple interactions between
miRNAs and epigenetic factors in skeletal muscle development and in response to stimuli or disease.
Keywords: miRNA action with epigenetic factors; miRNAs and DNA methylation; miRNAs and
HATs/HDACs; miRNAs and PRC2/Ezh2/Prmts
1. Introduction
Numerous studies have demonstrated the importance of epigenetic mechanisms in regulating
the development and the responses to external stimuli in virtually any cell type. By remodeling the
chromatin structure or gene expression, epigenetics cooperates with transcription factors and the
translational machinery in fine-tuning gene expression. Cells are often paused in a primed state
through epigenetic mechanisms, and their activation is triggered by external stimuli. For instance,
quiescent skeletal muscle stem cells are primed for myogenesis, as they display permissive marks
for gene transcription, coupled with a lack of repressive chromatin marks in several genes [1].
Indeed, by modulating the last steps of gene expression, cells can rapidly respond to stress or demands.
At the same time, epigenetics explains some phenotypes caused by bad habits. An example is the
appearance of metabolic dysfunction, which can be reversed by exercise, in the offspring of mice fed
with a high-fat diet, due to epigenetic modifications in the promoter of one of the metabolic master
regulators, peroxisome proliferator-activated receptor γ coactivator-1α [2]. In this article, we review
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miRNAs, among the different epigenetic mechanisms, focusing on the interplay between miRNAs and
other epigenetic players in skeletal muscle development and in response to pathological conditions.
1.1. MicroRNAs
miRNAs belong to the category of small, regulatory, non-coding RNA molecules, which also
include small interfering RNAs and repeat-associated siRNAs. miRNAs are mostly located within the
cell, although, recently some of them have also been found extracellularly, in biological fluids and cell
culture media [3]. The mechanisms of miRNA selective release are largely unknown, as well as their
function in distant cell-to-cell communication. However, it is clear that circulating miRNAs adopt some
protective mechanisms since they are resistant to high RNase activity of the extracellular environment
and some of them can be associated with patho-physiological conditions [4,5]. miRNAs can be found
in clusters and, therefore, transcribed as polycistronic primary transcripts, or as independent units,
including intergenic regions, exon sequences of non-coding transcripts, or intronic sequences of either
protein-coding or non-coding transcripts [6,7]. If miRNAs are located in an intronic region and have
the same direction as the host genes, they are generally transcribed simultaneously and excised by the
splicing machinery [8]. Certainly, transcribing intronic miRNAs may represent an efficient mechanism
for a protein-coding gene to regulate the expression of other proteins [9].
miRNAs are estimated to be responsible for the regulation of about 60% of human genes [10].
A single miRNA can target dozens of mRNAs, whereas individual mRNAs can be targeted by multiple
miRNAs, allowing for additional levels of complexity in gene expression regulation. miRNAs often
serve to fine-tune gene expression, but they have also been reported as being able to switch gene
expression on and off [11]. The miRNA region, which encompasses nucleotides 2–8 at the 5′ end,
defined as the seed region, is crucial for target recognition. Generally, the seed region completely pairs
at the 3′ untranslated region (UTR) of the target mRNAs [12], although miRNAs can also bind to the 5′
UTRs or to the coding regions of their target [13–19]. Moreover, some miRNA-target interactions do
not occur through the seed regions, but via non-canonical sites [20,21].
miRNAs regulate gene transcription via two main mechanisms which vary according to the degree
of complementarity between a miRNA and its target: high complementarity leads to mRNA cleavage
of the target through the RNA-induced silencing complex (RISC) [22], while low complementarity
induces translational inhibition of the mRNA target [23,24]. In animal cells, miRNAs predominantly
regulate gene expression via translational inhibition, either by interfering with the ribosome assembly
or by inducing its early dissociation [25–29]. In addition, miRNAs with partial complementarity to
their target mRNAs promote mRNA degradation via deadenylation, followed by decapping and the
ensuing exonucleolytic digestion [29–31].
It is difficult to establish how many miRNAs are encoded by the human genome, because of
their small size and nature (i.e., noncoding) and the different criteria used for miRNA annotation by
investigators. Several studies claim to have found thousands of mature miRNAs [32–34], while others
argue that in miRBase, the online repository for miRNAs, there are many false positives, i.e., sequences
that are not derived from authentic miRNA genes [35]. One of the most recent and comprehensive
analyses of human miRNA abundance in different tissues has profiled 1997 different mature miRNAs
for 61 tissues, by using a microarray platform for miRNA expression [34]. The vast majority of
miRNAs (>80%) showed an average abundance level throughout the tissues, about 10% showed
a high tissue-specific expression, indicating that miRNA expression is more tissue specific compared to
mRNA expression, while only one miRNA proved to be ubiquitously expressed. In addition, the high
expression of miR-1-3p, miR-133a-3p, miR-133b, and miR-206 in myocard and muscles was confirmed.
1.2. DNA Methylation
DNA methylation is an epigenetic mechanism of gene silencing achieved through the addition of
methyl groups to cytosines within CpG dinucleotides, frequently present in clusters in the genome [36].
DNA methylation, per se, does not imply transcriptional silencing; it acts as a docking site for the
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recruitment of other proteins and chromatin remodeling factors to repress gene expression [36].
During embryonic development, DNA methylation determines the maintenance of mono-allelic
silencing in genomic imprinting and X chromosome inactivation [37]. Indeed, the methylation
status differs from expressed and silenced genes and a loss of DNA methylation results in a loss
of imprinting [38]. During embryogenesis, few genes change their methylation status, except for those
expressed in the germline [39]. DNA methylation appears to be dispensable in undifferentiated cells,
whereas it is absolutely required in differentiated cells, as genetic deletion of DNA methyltransferase
results in embryonic or post-partum lethality [40]. Moreover, DNA methylation plays a pivotal
role in regulating gene expression in response to external stimuli, as in the expression of metabolic
or developmental genes in the offspring of pregnant mice exposed to different insults [2,41].
Further studies have delineated the biological impact of DNA methylation in cancer by silencing
DNA methyltransferases, or by treating cells with DNA demethylating agents [40]. For instance,
hyper-methylation has been proposed as a prognostic biomarker in acute lymphoblastic leukemia,
since it is associated with higher mortality rates [42].
1.3. Histone Modifications
Histones are not just structural proteins responsible for packing chromatin; they are active
regulators of gene expression and can undergo several post-translational and chemical modifications
that alter their physical interaction and spatial distribution. Histone modifications, which include
acetylation, methylation, phosphorylation, deimination, ubiquitylation, sumoylation, and ADP
ribosylation, affect the chromatin structure and create affinities for chromatin-associated proteins,
thereby modulating gene expression [43]. Histone modifications are responsible for the variation in the
expression of genes involved in diverse signaling pathways, regulating many cellular processes, such
as proliferation, differentiation, or repair [44]. Alteration in histone modifications are often associated
with diseases and are set to cause, or participate in, the onset and/or progression of pathological
states [45]. Specific combinations of histone modifications occurring on the same histone tail, or on
another tail, confer the overall expression status of a DNA region, a theory known as the “histone
code” [46]. The “histone code” is deciphered by specific proteins, able to bind to histone modifications,
and consequently remodel the chromatin structure.
The acetylation of lysine residues within histone tails, catalyzed by histone acetyltransferases
(HATs), neutralizes histone positive charges, hence, facilitating chromatin relaxation and increasing
the accessibility of transcription factors to their target genes [47]. The action of HAT is counteracted
by histone deacetylases (HDACs), which allow chromatin compaction and the repression of gene
transcription [48]. Generally, histone hypoacetylation and hypermethylation characterize silenced
DNA sequences, as in the inactive X chromosome in females or imprinted genes. Polycomb Repressive
Complex 2 (PRC2) drives trimethylation of histone 3 lysine 27 (H3K27me3), establishing gene
silencing at developmentally-regulated loci. Conversely, trithorax group proteins, which mediate the
trimethylation of histone 3 lysine 4 (H3K4me3), together with the histone lysine-specific demethylases,
antagonize PRC2 repressive activity and allow gene expression in specific cell types [49]. In muscle
stem cells, the absence of the repressive mark H3K27me3 across the genome and the concomitant
existence of H3K4me3 at the transcription start sites maintain chromatin in a primed state, allowing
cells to quickly respond to external stimuli [1]. Histone phosphorylation affects the “histone code” by
influencing the hierarchy of subsequent histone posttranslational modifications [50]. Indeed, not only
does histone phosphorylation dictate the precise spatiotemporal histone phosphorylation patterns
of adjacent serines or threonines, but it also influences the acetylation status and might affect the
readout of stable methylation marks at the neighboring lysine residues. Hence, it regulates the
binding of effector proteins to histones, during the cell cycle or in response to stress activation [51–53].
Citrullination is the post-translational conversion of a histone arginine residue to the non-coded
amino acid citrulline [54], thus affecting chromatin compaction and cellular processes. For instance,
it antagonizes arginine methylation during transcriptional activation [55], it regulates DNA damage
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response upon cellular stress [56], and it controls reprogramming efficiency by activating the
expression of key stem-cell genes during embryogenesis [57]. Moreover, histone ubiquitination
influences other posttranslational modifications, such as histone methylation [58], thus affecting gene
transcription [59]. Similarly, histone sumoylation cooperates with HDACs and mediates the repression
of gene transcription [60]. Instead, histone ADP-ribosylation directly destabilizes nucleosomes, leading
to the activation of gene transcription [61] and influencing DNA repair and cell replication [62].
1.4. MiRNAs and Epigenetics
miRNAs contribute to and are part of the epigenetic regulation of gene expression in at least
three different ways: first, the expression of miRNAs is regulated by multiple epigenetic mechanisms;
secondly, miRNAs can repress the expression of epigenetic factors; and thirdly, miRNAs and epigenetic
factors can cooperate to modulate common targets.
As for the coding regions, epigenetics also plays an important role in regulating miRNA expression.
About half of the miRNA genes encompass CpG islands. Some of them are regulated by DNA
methylation in tumors and in a cancer-specific fashion, such as miR-31 in breast cancer [63], or miR-124a
in colon cancer [64].
Several histone modifications have been involved in the regulation of miRNA expression in
cancer or during development [65]. Moreover, DNA methylation and histone modifications often
cooperate to regulate miRNA expression, as highlighted by experiments with HDAC inhibitors
together with DNA demethylating agents or DNA methylation inhibitors [65]. Interestingly, a feedback
regulation exists, since, in turn, some miRNAs are able to regulate the expression of epigenetic factors.
For example, the expression of DNA methyl transferases is repressed by the miR-29 or the miR-148
families [66,67]; histone-modifying enzymes are regulated by miR-449a, miR-101, and miR-137 [68–70].
These feedback regulations create a complex network between miRNAs and the epigenetic machinery,
which strengthens the epigenetic regulation of gene expression.
In this review, we discuss how miRNAs are regulated by, actively repress, or cooperate with
epigenetic factors in skeletal muscle.
2. MicroRNAs and DNA Methylation
DNA methylation and post-transcriptional gene silencing by miRNAs are two important
epigenetic mechanisms of skeletal muscle development and adaptation to diseases. There is evidence
that DNA methylation and miRNAs cooperate in the suppression of gene expression and protein
translation of common targets [71]. However, how these two major mechanisms combine to
influence skeletal muscle homeostasis and functioning remains unclear. Taking advantage of recent
deep-sequencing technologies, papers in which DNA methylation profile is compared with the full
spectrum of expressed miRNAs (miRNAome) and the consequent transcriptome network have started
to appear. The first-in-human study, where a coordinated action between promoter methylation and
miRNAs was suggested, was based on some considerations: (1) DNA methylation acts on the 5′
promoter region of a gene; (2) gene transcription typically depends on demethylation of the promoter
regions; and (3) miRNAs target the 3′ UTR to suppress gene expression. The authors hypothesized
the existence of a functional complementation between the methylation of promoter regions and the
post-transcriptional regulation guaranteed by miRNAs [71]. By systematic genome-wide examination,
it was shown that genes with a low methylation level have more miRNA binding sites on their mRNA
3′ UTRs, while genes that possess promoters with higher levels of DNA methylation are likely to avoid
miRNA regulation (Figure 1).
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Figure 1. Functional complementation between methylation of promoter regions and miRNA
post-transcriptional regulation. DNA methylation of promoter regions (a) and miRNA regulation
(b) are usually mutually exclusive. Red dots: promoter methylated sites; blue rectangles: miRNA
binding sites.
This report provides the first attempt to uncover such an important and complex regulation system.
Unlike many previous exploratory studies, focused on delineating the effects of a single epigenetic
mechanism on gene expression, this study aimed at understanding how DNA methylation and miRNA
reciprocally regulate the expression of target genes at the genome level. Although the results obtained
suggest a complementary relationship between DNA methylation and miRNA regulation, the way in
which the two mechanisms cooperate remains poorly understood.
An integrated genome-wide analysis of DNA methylation (methylome distribution), miRNAome
and mRNA transcripts in cattle skeletal muscle development has been carried out in order to investigate
the coordinated action of several epigenetic modifications [72]. This research, unlike the previous
ones, not only examined methylation in promoter regions, but also in gene bodies. As expected,
a negative correlation between core promoter methylation and gene expression has been found in
both fetal and adult bovine skeletal muscle. In fact, promoters of highly-expressed genes exhibited
low methylation levels, as in myosin light chain 2 (MYL2) or dystrobrevin binding protein (DTNBP1).
Instead, the promoters of lowly-expressed genes were usually highly methylated, as in the case of
cellular retinoic acid binding protein 2 (CRABP2) or laminin B1 (LAMB1). DNA methylation level was
higher in the adult bovine stage compared to the fetal period, and the differences in methylation degree
might have partially contributed to the progression through the different stages of muscle development.
Among the genes of interest were CRABP2, a key modulator of skeletal muscle differentiation,
and MYL2, a well-known gene related to the biosynthesis of myosin. While gene body DNA
methylation positively correlates with gene expression, its functional role is still unknown and does not
allow drawing any causal conclusion. It is worth noting that, contrary to the previous study, the average
methylation levels were higher for the miRNA-targeted genes than for the non-miRNA-targeted ones,
in both fetal and adult bovine libraries. These results suggest that miRNA activity on target genes may
somehow encourage methylation of the gene, or, that it is so important to repress certain genes during
development that both DNA methylation and miRNAs are in place to fully switch their expression
off. By using the integrated approach between analyses of methylome and miRNAs, this study has
also confirmed the importance of some miRNAs, such as miR-1, miR-133, and miR-206, in targeting
multiple genes related to muscle development. The aim of this study not only was to confirm or
identify new possible muscle development-related genes, but also to highlight the combined action of
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DNA methylation and miRNA post-transcriptional regulation which have, so far, been investigated
individually or analyzed focusing on restricted target genes in muscle development.
Epigenetics fine-tunes gene expression in response to extracellular stimuli or pathological states.
Several reports have described dynamic changes in DNA methylation pattern and miRNA expression
in diseases, which may contribute to the pathogenic progression and, therefore, be targeted by new
therapeutic strategies. Increasing evidence has pointed to miRNAs role in the post-transcriptional
regulation of gene expression in skeletal muscle response to exercise [73–75]. Furthermore, both acute
and chronic exercises have a significant impact on DNA methylation, in a tissue- and gene-specific
manner in humans [76]. A comprehensive analysis of these epigenetic mechanisms has been conducted
in a recent study on skeletal muscle of type 2 diabetes mellitus (T2D) patients, following chronic exercise
training [77]. Microarray analyses were performed on skeletal muscle of obese Polynesian patients
with T2D, before and after 16 weeks of endurance or resistance exercise, generating epigenomic
and transcriptomic networks. Modulation of DNA methylation and miRNA expression was higher
after endurance training and was related with metabolic and microvascular plasticity, important
to diabetes rehabilitation. Both resistance and endurance training induced hypomethylation of the
DNA, despite affecting the genes involved in different molecular pathways. Namely, in response to
endurance training, differential methylation mostly affected the genes related to lipid and carbohydrate
metabolism, metabolic diseases, cell death, and survival. On the contrary, the top-ranked functional
networks and categories responding to resistance training were cellular assembly and organization,
cellular development, tissue morphology and cardiovascular system development and function.
At the same time, endurance and resistance training induced changes in the expression of 25 and
23 miRNAs, respectively. The analysis of the predicted targets suggests that miRNAs regulate the
genes involved in the regulation of transcription, lipid and glucose metabolism, and myofibril and
connective tissue development in response to endurance training. The targets involved in controlling
gene expression and blood vessel development were influenced by resistance training. The authors
concluded that extensive metabolic and molecular reprogramming are more pronounced in response
to chronic endurance training than in the resistance one, which indicates greater efficiency in diabetes
rehabilitation. Integrating transcriptome and methylome analyses supported the hypothesis that DNA
methylation and miRNA expression cooperate in the metabolic plasticity of skeletal muscle in response
to endurance training. In particular, the metabolic reprogramming, evinced by the transcriptome
analysis, was connected to epigenetic regulation by downregulated miR-29a and an overrepresented
metabolic methylome [77].
3. MicroRNAs and Histone Modifications
Various miRNAs control the chromatin structure by affecting the “histone code” and targeting
key enzymes, known as histone modifiers. Furthermore, histone modifications are directly involved in
the regulation of cell-specific expression of miRNAs and modulate their levels in various physiological
and pathological conditions [44,45]. The connection between miRNAs and histone modifications has
undoubtedly added a new layer of regulation to the already-existing knowledge about modulation of
cellular processes.
3.1. MicroRNAs and Histone Acetylation/Deacetylation
The interplay between miRNAs and HATs/HDACs, as well as the coordinated actions of the two
epigenetic mechanisms, play a paramount role in myogenesis, especially during muscle development.
One of the miRNAs involved in myogenesis is miR-1, which promotes muscle regeneration also
by targeting HDAC4 [78] that, in turn, inhibits the expression of the myogenic factor Myocyte
enhancer factor 2 (MEF2) [79]. Similarly, miR-29 promotes myogenesis through the inhibition of the
transcriptional regulator Ying Yang 1 (YY1), which, in conjunction with the epigenetic factors PRC2 and
HDAC1, acts as a repressor of muscle-specific gene expression [80]. Interestingly, YY1 is also a target
of miR-1 and represses the expression of miR-1, miR-133, and miR-206 in myoblast, by recruiting
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PRC2 on their promoters [81]. miR-206 promotes myoblast differentiation by repressing Pax7 [78],
and its expression is strictly controlled by HDAC1 during myogenesis [82]. Thus, miRNAs regulate
the expression of HDACs and other chromatin remodeling factors, creating regulatory circuitries that
supervise and reinforce the epigenetic regulation of gene expression in myogenesis (Figure 2).
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Indeed, the expression of HDAC4 was significantly upregulated in skeletal muscle following
denervation [89] and in ALS patients [90]. Moreover, HDAC4 expression in skeletal muscle positively
correlated with the ALS progression rate and inversely correlated with the extent of reinnervation [90],
confirming the negative role of muscle HDAC4 in the reinnervation process in ALS patients.
3.2. MicroRNAs and Histone Methylation
The role of microRNAs and histone methylation during myogenesis has been extensively studied
in recent years. Various miRNAs modulate chromatin structure and gene transcription by regulating
histone methylation. In a study in which the expression of miRNAs from proliferating myoblasts
to terminally-differentiated myotubes was analyzed, miR-26a was identified as upregulated during
myogenesis [79]. By using a bioinformatics approach, a subunit of PRC2 complex, Ezh2, was identified
as a possible miR-26a target gene. Coherently, the expression of miR-26a and Ezh2 inversely correlated
during muscle differentiation. Prior to myogenesis, the histone methyltransferase Ezh2, along with
YY1 and HDAC1, bound to the E-box regions of muscle-specific gene promoters, causing their silencing
primarily through H3K27 three-methylation. Upon activation of myogenesis, the Ezh2-containing
complex disassociated from chromatin, maintaining the accessibility of the promoter regions to
transcriptional activators. Therefore, an increased level of miR-26a during myogenesis serves to
post-transcriptionally repress Ezh2 so that it is no longer able to elicit its suppressive effects on
myogenesis [91] (Figure 3). However, this study does not clarify the mechanism completely. It is still
unclear whether miR-26a-mediated Ezh2 mRNA suppression causes the decrease in Ezh2 protein
expression observed during myogenesis or whether the decline in Ezh2 protein acts as a negative
feedback, causing the decrease in Ezh2 mRNA expression. In addition to miR-26a, the Ezh2 3′
UTR is also targeted by miR-214 [92]. It is likely that miR-214 and miR-26a repress Ezh2 at distinct
developmental steps. Both miR26a and miR-214 affect Ezh2 and, in turn, they are modulated by Ezh2
in a negative feedback loop. While miR-26a may be relevant at later stages of differentiation, as its
expression occurs in terminally-differentiated muscle cells, miR-214 accumulation is observed at the
very initial stages of cell differentiation. A working model in which the downregulation of Ezh2, taking
place at the initial phase of muscle differentiation, together with MyoD and/or myogenin recruitment,
promotes the expression of miR-214 has been proposed (Figure 3). While in myoblasts, PRC2 binds
and represses miR-214 transcription, during differentiation, PRC2 is disengaged and MyoD/myogenin
are recruited at the miR-214 promoter region, promoting its transcription. After being transcribed,
miR-214 loops back to target the Ezh2 3′ UTR, thus reducing Ezh2 protein accumulation.
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enough to effectively and rapidly reduce Ezh2 availability at critical stages as those regulating 
skeletal muscle cell differentiation. 
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Int. J. Mol. Sci. 2017, 18, 840 9 of 14
Thus, miR-214 can impact the transcription controlled by PRC2, by regulating Ezh2 protein levels,
introducing an additional level of PRC2 regulation via a post-transcriptional mechanism. This network
motif, named the two-node bistable feedback loop [93], ensures that the system is robust enough to
effectively and rapidly reduce Ezh2 availability at critical stages as those regulating skeletal muscle
cell differentiation.
Another study highlighted the connection between the arginine methyltransferases (Prmts) and
the myogenic miRNA expression [94]. Prmt5 is required for myogenin transcription, therefore, it is
indirectly indispensable for the expression of myogenic miRNAs (miR-1-1/2 and miR-133a-1/2) [95].
By contrast, Prmt4 directly binds to, and modifies, histones in myogenic miRNA regulatory sequences,
and is the requisite for the binding of both SWI/SNF and myogenin transcription factors. Moreover,
Prmt4 binds to, and is required, for the expression of genes at later stages of skeletal muscle
differentiation [95,96]. This is another example of how histone-modifying enzymes and miRNAs
cooperate during myogenesis.
4. Conclusions
There has been growing interest in epigenetic mechanisms in recent years, highlighting
the importance of epigenetics in regulating developmental signaling, as well as cellular adaptation
to external stimuli or diseases. In the last decade, the study of miRNA biology has attracted
remarkable attention, resulting in rapid advances. The increasing literature exploring the role of
miRNAs has clarified their biological functions and involvement in pathological states, suggesting that
miRNAs may be used as targets for therapeutic approaches or biomarkers for diagnosis. By studying
epigenetic mechanisms, cooperated actions between miRNAs and other epigenetic factors have
emerged, depicting a more complex and sophisticated layer of gene regulation. Thanks to the advances
in new generation sequencing, integrated multi-omic analyses have started to define the interaction
between miRNAs and epigenetic factors, discovering coordinated circuitries that modulate gene
expression during myogenesis and in disease. These studies will facilitate the development of novel,
combined approaches to prevent or treat skeletal muscle in several disease conditions.
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